Cross-protection against drifted influenza viruses

References

• Stöhr K. Influenza--WHO cares. Lancet Infect Dis 2002; 2:517; http://dx.doi.org/10.1016/S1473-3099(02)00366-3; PMID: 12206966
   PubMed Web of Science ®Google Scholar
• Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51:407 - 21; http://dx.doi.org/10.1146/annurev.med.51.1.407; PMID: 10774473
   PubMed Web of Science ®Google Scholar
• Both GW, Sleigh MJ, Cox NJ, Kendal AP. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 1983; 48:52 - 60; PMID: 6193288
   PubMed Web of Science ®Google Scholar
• Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417 - 27; http://dx.doi.org/10.1016/0092-8674(82)90135-0; PMID: 6186384
   PubMed Web of Science ®Google Scholar
• Cox NJ, Black RA, Kendal AP. Pathways of evolution of influenza A (H1N1) viruses from 1977 to 1986 as determined by oligonucleotide mapping and sequencing studies. J Gen Virol 1989; 70:299 - 313; http://dx.doi.org/10.1099/0022-1317-70-2-299; PMID: 2732691
   PubMed Web of Science ®Google Scholar
• Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373 - 8; http://dx.doi.org/10.1038/289373a0; PMID: 6162101
   PubMed Web of Science ®Google Scholar
• Wang ML, Skehel JJ, Wiley DC. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J Virol 1986; 57:124 - 8; PMID: 3941436
   PubMed Web of Science ®Google Scholar
• Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350:218 - 20; http://dx.doi.org/10.1056/NEJMp038238; PMID: 14724300
   PubMed Web of Science ®Google Scholar
• Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 2006; 314:1898 - 903; http://dx.doi.org/10.1126/science.1132745; PMID: 17185596
   PubMed Web of Science ®Google Scholar
• Aymard M, Valette M, Lina B, Thouvenot D. Surveillance and impact of influenza in Europe. Groupe Régional d’Observation de la Grippe and European Influenza Surveillance Scheme. Vaccine 1999; 17:Suppl 1 S30 - 41; http://dx.doi.org/10.1016/S0264-410X(99)00103-6; PMID: 10471178
   PubMedGoogle Scholar
• Klimov A, Simonsen L, Fukuda K, Cox N. Surveillance and impact of influenza in the United States. Vaccine 1999; 17:Suppl 1 S42 - 6; http://dx.doi.org/10.1016/S0264-410X(99)00104-8; PMID: 10471179
   PubMedGoogle Scholar
• Ansaldi F, Icardi G, Gasparini R, Campello C, Puzelli S, Bella A, et al. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season. J Clin Microbiol 2005; 43:3027 - 9; http://dx.doi.org/10.1128/JCM.43.6.3027-3029.2005; PMID: 15956452
   PubMed Web of Science ®Google Scholar
• Paget WJ, Meerhoff TJ, Meijer A, EISS. Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season. Euro Surveill 2005; 10:107 - 11; PMID: 15879646
   PubMedGoogle Scholar
• Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332 - 42; http://dx.doi.org/10.1093/cid/cis431; PMID: 22539661
   PubMed Web of Science ®Google Scholar
• de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61:94 - 9; http://dx.doi.org/10.1002/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C; PMID: 10745239
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Banfi F, Durando P, Sticchi L, Icardi G, et al. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol 2006; 13:162 - 4; http://dx.doi.org/10.1128/CVI.13.1.162-164.2006; PMID: 16426017
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063 - 5; http://dx.doi.org/10.1016/j.vaccine.2006.01.015; PMID: 16464520
   PubMed Web of Science ®Google Scholar
• Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24:5966 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.05.009; PMID: 16777274
   PubMed Web of Science ®Google Scholar
• Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655 - 63; http://dx.doi.org/10.1001/jama.284.13.1655; PMID: 11015795
   PubMed Web of Science ®Google Scholar
• Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006; 24:6605 - 11; http://dx.doi.org/10.1016/j.vaccine.2006.05.063; PMID: 16806607
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine–Colorado, December 2003. WR Morb Mortal Wkly Rep 2004; 53:8 - 11
   PubMedGoogle Scholar
• Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008; 118:3273 - 5; PMID: 18802488
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659 - 63; http://dx.doi.org/10.1016/j.vaccine.2006.08.026; PMID: 17011678
   PubMed Web of Science ®Google Scholar
• Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21:1268 - 74; http://dx.doi.org/10.1016/S0264-410X(02)00401-2; PMID: 12559808
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25:3955 - 61; http://dx.doi.org/10.1016/j.vaccine.2007.02.045; PMID: 17383057
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937 - 43; http://dx.doi.org/10.1016/S0140-6736(00)05066-2; PMID: 11425416
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210 - 5; http://dx.doi.org/10.1086/428948; PMID: 15776364
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, et al. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012; 30:2908 - 13; http://dx.doi.org/10.1016/j.vaccine.2012.02.003; PMID: 22342501
   PubMed Web of Science ®Google Scholar
• Straight TM, Ottolini MG, Prince GA, Eichelberger MC. Evidence of a cross-protective immune response to influenza A in the cotton rat model. Vaccine 2006; 24:6264 - 71; http://dx.doi.org/10.1016/j.vaccine.2006.05.092; PMID: 16860444
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612 - 20; http://dx.doi.org/10.1016/j.vaccine.2006.08.036; PMID: 17005299
   PubMed Web of Science ®Google Scholar
• Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003; 21:3212 - 8; http://dx.doi.org/10.1016/S0264-410X(03)00234-2; PMID: 12804850
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513 - 22; http://dx.doi.org/10.1056/NEJMoa061850; PMID: 17167134
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al, CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. [Erratum in: N Engl J Med 2007; 356] [12] N Engl J Med 2007; 356:685 - 96; http://dx.doi.org/10.1056/NEJMoa065368; PMID: 17301299
   PubMed Web of Science ®Google Scholar
• Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475 - 81; http://dx.doi.org/10.1016/j.vaccine.2005.08.012; PMID: 16150518
   PubMed Web of Science ®Google Scholar
• Webster RG. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis 1999; 28:225 - 9; http://dx.doi.org/10.1086/515123; PMID: 10064231
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997; 15:865 - 8; http://dx.doi.org/10.1016/S0264-410X(96)00268-X; PMID: 9234535
   PubMed Web of Science ®Google Scholar
• Macklin MD, McCabe D, McGregor MW, Neumann V, Meyer T, Callan R, et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 1998; 72:1491 - 6; PMID: 9445052
   PubMed Web of Science ®Google Scholar
• Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol 1995; 69:7712 - 7; PMID: 7494280
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1:583 - 7; http://dx.doi.org/10.1038/nm0695-583; PMID: 7585127
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011; 92:128 - 40; http://dx.doi.org/10.1099/vir.0.023242-0; PMID: 21169215
   PubMed Web of Science ®Google Scholar
• Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008; 180:7019 - 27; PMID: 18453624
   PubMed Web of Science ®Google Scholar
• Luke JM, Simon GG, Söderholm J, Errett JS, August JT, Gale M Jr., et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85:1370 - 83; http://dx.doi.org/10.1128/JVI.01250-10; PMID: 21106745
   PubMed Web of Science ®Google Scholar
• Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011; 146:448 - 61; http://dx.doi.org/10.1016/j.cell.2011.06.041; PMID: 21782231
   PubMed Web of Science ®Google Scholar
• Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162:171 - 82; http://dx.doi.org/10.1016/j.jbiotec.2012.08.012; PMID: 22981627
   PubMed Web of Science ®Google Scholar
• Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3:157 - 64; http://dx.doi.org/10.4161/hv.3.5.4175; PMID: 17637571
   PubMed Web of Science ®Google Scholar
• Liu X, Guo J, Han S, Yao L, Chen A, Yang Q, et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012; 30:6527 - 33; http://dx.doi.org/10.1016/j.vaccine.2012.08.054; PMID: 22959982
   PubMed Web of Science ®Google Scholar
• Hikono H, Miyazaki A, Mase M, Inoue M, Hasegawa M, Saito T. Induction of a cross-reactive antibody response to influenza virus M2 antigen in pigs by using a Sendai virus vector. Vet Immunol Immunopathol 2012; 146:92 - 6; http://dx.doi.org/10.1016/j.vetimm.2012.01.017; PMID: 22336036
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060 - 4; http://dx.doi.org/10.1126/science.1192517; PMID: 20647428
   PubMed Web of Science ®Google Scholar
• Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 2005; 79:7380 - 8; http://dx.doi.org/10.1128/JVI.79.12.7380-7388.2005; PMID: 15919893
   PubMed Web of Science ®Google Scholar
• Bruzzone B, Crovari P, Durando P, Setti M. [Influenza vaccination: advantages of new generation carriers]. Ann Ig 2002; 14:Suppl 3 11 - 8; PMID: 12389406
   PubMedGoogle Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673 - 80; http://dx.doi.org/10.1016/S0264-410X(00)00499-0; PMID: 11257408
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197 - 203; http://dx.doi.org/10.1586/14760584.2.2.197; PMID: 12899571
   PubMedGoogle Scholar
• Bloch KE. Sterol structure and membrane function. CRC Crit Rev Biochem 1983; 14:47 - 92; http://dx.doi.org/10.3109/10409238309102790; PMID: 6340956
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13:1010 - 3; http://dx.doi.org/10.1128/CVI.00191-06; PMID: 16960112
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209 - 22; http://dx.doi.org/10.1016/j.vaccine.2008.03.093; PMID: 18462843
   PubMed Web of Science ®Google Scholar
• Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253 - 9; http://dx.doi.org/10.1128/CVI.00316-07; PMID: 18003811
   PubMed Web of Science ®Google Scholar
• Baldo V, Menegon T, Bonello C, Floreani A, Trivello R, Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19:3472 - 5; http://dx.doi.org/10.1016/S0264-410X(01)00060-3; PMID: 11348713
   PubMed Web of Science ®Google Scholar
• Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.02.004; PMID: 19840662
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563 - 71; http://dx.doi.org/10.1097/INF.0b013e31819d6394; PMID: 19561422
   PubMed Web of Science ®Google Scholar
• Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639 - 51; http://dx.doi.org/10.1517/14712591003724662; PMID: 20218923
   PubMed Web of Science ®Google Scholar
• Novartis. Vaccine and diagnostics. Data on file; 2007.
   Google Scholar
• Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003; 21:4234 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00456-0; PMID: 14505903
   PubMed Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:ra5; http://dx.doi.org/10.1126/scitranslmed.3000624; PMID: 20371470
   PubMed Web of Science ®Google Scholar
• Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133 - 8; http://dx.doi.org/10.1016/j.virusres.2004.02.025; PMID: 15163501
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:1525 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.01.019; PMID: 18294741
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27:3345 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.01.081; PMID: 19200846
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R, Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007; 27:542 - 7; http://dx.doi.org/10.1007/s10875-007-9100-4; PMID: 17514499
   PubMed Web of Science ®Google Scholar
• Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, Mak KH, et al. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis 2002; 185:1005 - 10; http://dx.doi.org/10.1086/340044; PMID: 11930308
   PubMed Web of Science ®Google Scholar
• Brauer V, Laghi-Pasini F, Capecchi PL, et al. Priming for pandemic influenza: Antigen-sparing MF59-adjuvanted A / H5N1 vaccine induces immunological memory and shows cross-reactive potential in adults including the elderly. 13th International Congress on Infectious Diseases 2008, Kuala Lumpur, Malaysia, 19–22 June 2008.
   Google Scholar
• Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687 - 93; http://dx.doi.org/10.1016/S0264-410X(02)00632-1; PMID: 12639491
   PubMed Web of Science ®Google Scholar
• Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527 - 33; http://dx.doi.org/10.1093/aje/kws313; PMID: 22940713
   PubMed Web of Science ®Google Scholar
• Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al, H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428 - 35; http://dx.doi.org/10.1016/j.vaccine.2009.07.102; PMID: 19683087
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740 - 5; http://dx.doi.org/10.1016/j.vaccine.2009.12.014; PMID: 20034605
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849 - 57; http://dx.doi.org/10.1016/j.vaccine.2009.10.017; PMID: 19835828
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665; http://dx.doi.org/10.1371/journal.pone.0001665; PMID: 18301743
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580 - 9; http://dx.doi.org/10.1016/S0140-6736(07)61297-5; PMID: 17707753
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284 - 90; http://dx.doi.org/10.1016/j.vaccine.2009.01.040; PMID: 19856521
   PubMed Web of Science ®Google Scholar
• Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378 - 88; http://dx.doi.org/10.1016/j.vaccine.2008.02.068; PMID: 18407382
   PubMed Web of Science ®Google Scholar
• Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 2009; 27:4381 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.05.029; PMID: 19450630
   PubMed Web of Science ®Google Scholar
• Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002; 20:Suppl 5 B17 - 23; http://dx.doi.org/10.1016/S0264-410X(02)00512-1; PMID: 12477413
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010:517198; http://dx.doi.org/10.1155/2010/517198; PMID: 20369059
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650 - 8; http://dx.doi.org/10.1086/590434; PMID: 18652550
   PubMed Web of Science ®Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201 - 14; http://dx.doi.org/10.1586/14760584.7.8.1201; PMID: 18844594
   PubMed Web of Science ®Google Scholar
• Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum Vaccin Immunother 2012; 8:67 - 75; PMID: 22293531
   PubMed Web of Science ®Google Scholar
• Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012; 11:17 - 25; http://dx.doi.org/10.1586/erv.11.154; PMID: 22149703
   PubMed Web of Science ®Google Scholar
• Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, et al, Italian Intradermal Influenza Vaccine Working Group. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Adv Ther 2012; 29:312 - 26; http://dx.doi.org/10.1007/s12325-012-0012-1; PMID: 22529024
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346 - 54; http://dx.doi.org/10.4161/hv.6.4.10961; PMID: 20372053
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.06.010; PMID: 21699951
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, et al, VRC 304 and VRC 305 Study Teams. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792 - 7; http://dx.doi.org/10.1128/CVI.05663-11; PMID: 22956656
   PubMed Web of Science ®Google Scholar
• Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis 2012; 206:1069 - 77; http://dx.doi.org/10.1093/infdis/jis402; PMID: 22891287
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28:4123 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.04.030; PMID: 20433807
   PubMed Web of Science ®Google Scholar